ArticleJournal of thoracic disease2025
USP7-mediated stabilization of CXCL3 aggravates inflammation in models of acute lung injury.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: CXCL3 is involved in the pathogenesis of asthmatic lungs; however, its specific function in sepsis-induced acute lung injury (ALI) remains unclear. This study aimed to elucidate the modulatory function of CXCL3 and its relationship to the deubiquitinating enzyme USP7 in lung inflammation. As model systems, we used lipopolysaccharide (LPS) stimulation of human lung microvascular endothelial cells (HLMVECs) and macrophages in vitro and a mouse model of sepsis-induced ALI. Methods: Cell behavior was assessed using Cell Counting Kit-8, 5-Ethynyl-2'-deoxyuridine assays, flow cytometry, biochemical, and Western blotting assays. STAT3-binding sites on CXCL3 were predicted via the JASPAR database. Interactions between CXCL3, STAT3, and USP7 were confirmed through chromatin immunoprecipitation, dual-luciferase, and co-immunoprecipitation assays. Results: CXCL3 expression was substantially increased in ALI. CXCL3 knockdown could improve LPS-induced apoptosis, inflammatory responses, and oxidative stress, and inhibited the M1 polarization of THP-1 cells. STAT3 activated CXCL3 transcription, while USP7 modulated CXCL3 through deubiquitination. USP7 silencing alleviated LPS-induced HLMVEC injury and inhibited M1 macrophage polarization through the regulation of CXCL3. USP7 depletion inactivated the NF-κB pathway by regulating CXCL3. Furthermore, CXCL3 knockdown ameliorated cecal ligation and puncture (CLP)-induced lung injury Conclusions: CXCL3 knockdown ameliorated sepsis-induced ALI. In
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.